![\"Scientist](\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/17c00d4e54e6a5a1bcf7578f7ff9b45a\/%3Furl%3Dhttps%253a%252f%252fg.foolcdn.com%252feditorial%252fimages%252f841984%252fscientist-in-lab-coat-studies-a-test-tube-of-fluid-while-looking-at-a-strand-of-dna-on-a-computer-screen.jpg%26amp%3Bw%3D700\"\/)
<\/p>\n
Image source: Getty Images.<\/p>\n
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue \u00bb<\/a><\/p>\n One drug, two clinical trials<\/p>\n Conducted over more than 96 weeks, the first trial “significantly reduced the annualized relapse rate (ARR) compared to teriflunomide,” an RMS drug developed by Sanofi and currently available as a generic from multiple manufacturers.<\/p>\n The second trial compared fenebrutinib to ocrelizumab, an MS drug developed by Roche itself and not available as a generic, in treatment of PPMS. This trial confirmed fenebrutinib is at least “non-inferior compared to ocrelizumab,” which in turn is currently “the only approved therapy in PPMS.” This second trial lasted more than 120 weeks.<\/p>\n Overall, Roche says “fenebrutinib substantially reduced the number of relapses in RMS and slowed disability progression in PPMS” — two separate uses for one MS drug in a market that’s been estimated at $27.8 billion in annual sales last year, with likely growth to $46.4 billion by 2033.<\/p>\n Clinical trial work<\/a> on fenebrutinib is ongoing.<\/p>\n Is Roche stock a buy?<\/p>\n Valued in excess of $296 billion, Roche stock sells for 25.3 times trailing earnings but less than 15 times free cash flow<\/a>. (At $19.9 billion generated over the past year, Roche generates nearly 70% more cash profit than it reports as net income.) The company also pays a very respectable 3.8% dividend yield<\/a>.<\/p>\n Were Roche growing just a bit faster than the 6% annualized long-term growth rate that analysts project for it, the stock might already be a buy. As things stand, though, I still need to see Roche stock get cheaper before I can call it a buy.<\/p>\n Should you invest $1,000 in Roche Holding AG right now?<\/p>\n Before you buy stock in Roche Holding AG, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Roche Holding AG wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $595,194!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,153,334!*<\/p>\n Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,036% \u2014 a market-crushing outperformance compared to 191% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of November 10, 2025<\/p>\n Rich Smith<\/a> has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy<\/a>.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":"Key Points Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today.…\n","protected":false},"author":2,"featured_media":13539,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[114,166,39,167,160,161,162,163,9228,3325,134,7986,164,165,436],"class_list":["post-13538","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-business","tag-business-news","tag-economy","tag-finance","tag-financial-information","tag-investing","tag-investor","tag-market-news","tag-motley-fool","tag-press-releases","tag-roche","tag-sedar","tag-stock-research","tag-stock-valuation","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=13538"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/13538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/13539"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=13538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=13538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=13538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}